NUR 603 Module 4 Study Design Critique Example

Two Designs, Two Answers: What the Vitamin D Observational Studies and the VITAL Trial Can Each Claim

[Student Name]

Southern New Hampshire University

NUR 603: Epidemiology

Module Four Study Design Critique

[Instructor Name]

[Date]

Two Designs, Two Answers: What the Vitamin D Observational Studies and the VITAL Trial Can Each Claim

For more than a decade, vitamin D seemed to protect against nearly everything. People with higher blood levels had less cancer, less heart disease and longer lives in study after study, and supplements became one of the most commonly recommended pills in primary care. When a large randomized trial finally tested the idea, it found little benefit. This critique examines why well-conducted observational studies and a well-conducted trial disagreed. It argues that the disagreement is not a failure of either design but a lesson in what each design can and cannot claim, and that the trial answers the question patients actually ask.

The Observational Evidence

Gandini et al. (2011) pooled observational studies relating serum 25-hydroxyvitamin D to cancer. For colorectal cancer, based on 2,630 cases in nine studies, each 10 ng/mL increase in serum level was associated with a summary relative risk of 0.85, a 15% lower risk. For breast cancer, the pooled estimate was 0.89, but the authors noted a telling split: case-control studies gave a strong association, with a relative risk of 0.83, while prospective studies gave almost none, at 0.97. No association was found for prostate cancer.

The designs behind these numbers matter. In a prospective cohort, blood is drawn from healthy people who are then followed to see who develops cancer. In a case-control study, blood is drawn from people who already have cancer and compared with blood from people who do not. Both designs observe vitamin D levels as they happen to be; neither assigns them. At best, they can show that a level is associated with an outcome and estimate how strongly.

The Trial

The Vitamin D and Omega-3 Trial randomized 25,871 men aged 50 and older and women aged 55 and older across the United States to vitamin D3 at 2,000 IU a day or placebo, using a factorial design that also tested omega-3 fatty acids (Manson et al., 2019). About 5,100 participants were Black, a strength given how often trials underrepresent them. Over a median follow-up of 5.3 years, invasive cancer occurred in 793 participants in the vitamin D group and 824 in the placebo group, a hazard ratio of 0.96 with a 95% confidence interval from 0.88 to 1.06. Major cardiovascular events occurred in 396 and 409 participants, a hazard ratio of 0.97. Neither primary end point was reduced.

Randomization is what gives the trial its authority. By assigning vitamin D by chance, it balances the groups on factors that were measured and, on average, on factors that were not, so a gap in cancer or heart events between the arms can be laid at the door of the supplement itself. That is precisely what the observational studies could not do. The trial also measured adherence and outside supplement use, since placebo participants were allowed a modest dose of their own, and its analysis kept every participant in their original arm. Both choices protect the comparison from the bias that arises when healthier people are more likely to keep taking a pill.

Why the Designs Disagreed

The first explanation is confounding. People with high vitamin D levels tend to spend more time outdoors, exercise more, weigh less and smoke less, and each of these is linked to lower cancer and heart disease risk. Studies adjust for the confounders they measure, but adjustment is never complete, and residual confounding by general health can produce an association that disappears when vitamin D is assigned at random.

The second is reverse causation. Autier et al. (2014) reviewed observational studies and trials across many conditions and concluded that low vitamin D is more likely a marker of ill health than a cause of it. Inflammation lowers serum 25-hydroxyvitamin D, and people who are becoming ill go outdoors less. In that case, disease or its early stages lower vitamin D, rather than low vitamin D causing disease.

The third is the timing of measurement, which explains the split in the breast cancer results. In case-control studies, blood is drawn after diagnosis, when the cancer, its treatment and the changes in daily life it brings can already have lowered vitamin D. Prospective studies avoid this problem by drawing blood before disease, and their weaker association fits the view that part of the case-control signal was an effect of the disease on the measurement (Gandini et al., 2011).

Limits of the Trial

The trial has limits of its own. Most participants were not deficient at the start, so it cannot rule out benefit in people with very low levels. Five years may be too short for an effect on cancer incidence, which develops over decades, and the trial tested one dose. A secondary analysis suggested a possible reduction in cancer deaths, but secondary results are hypothesis-generating and should not be read as proof. These limits narrow the trial's answer; they do not reverse it. For generally healthy older adults, taking vitamin D to prevent cancer or heart disease is not supported.

What Each Design Can Claim

The observational studies can claim that higher vitamin D levels are associated with lower colorectal cancer risk in the populations studied. They cannot claim that raising vitamin D would lower that risk. The trial can claim that giving 2,000 IU a day to a broad population of older adults did not reduce cancer or cardiovascular events over about five years. It cannot claim that vitamin D is irrelevant to health, since it did not test people with deficiency separately. Writing within these limits means using association verbs, such as linked or associated, for the cohorts and effect verbs, such as reduced or did not reduce, only for the trial.

Conclusion

The vitamin D story shows why association is not enough to justify an intervention. Confounding, reverse causation and the timing of measurement can all create associations that a randomized trial does not confirm. For a patient who asks whether to take vitamin D to prevent cancer, the best evidence says it is unlikely to help unless there is a separate reason, such as deficiency or bone health, to take it.

References

Autier, P., Boniol, M., Pizot, C., & Mullie, P. (2014). Vitamin D status and ill health: A systematic review. The Lancet Diabetes & Endocrinology, 2(1), 76-89. https://doi.org/10.1016/S2213-8587(13)70165-7

Gandini, S., Boniol, M., Haukka, J., Byrnes, G., Cox, B., Sneyd, M. J., Mullie, P., & Autier, P. (2011). Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. International Journal of Cancer, 128(6), 1414-1424. https://doi.org/10.1002/ijc.25439

Manson, J. E., Cook, N. R., Lee, I.-M., Christen, W., Bassuk, S. S., Mora, S., Gibson, H., Gordon, D., Copeland, T., D'Agostino, D., Friedenberg, G., Ridge, C., Bubes, V., Giovannucci, E. L., Willett, W. C., & Buring, J. E. (2019). Vitamin D supplements and prevention of cancer and cardiovascular disease. New England Journal of Medicine, 380(1), 33-44. https://doi.org/10.1056/NEJMoa1809944